Your browser doesn't support javascript.
loading
The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy / 中国天然药物
Chinese Journal of Natural Medicines (English Ed.) ; (6): 801-810, 2018.
Article in English | WPRIM | ID: wpr-812348
ABSTRACT
Chemokine 12 (CXCL12), also known as stromal cell derived factor-1 (SDF-1) and a member of the CXC chemokine subfamily, is ubiquitously expressed in many tissues and cell types. It interacts specifically with the ligand for the transmembrane G protein-coupled receptors CXCR4 and CXCR7. The CXCL12/CXCR4 axis takes part in a series of physiological, biochemical, and pathological process, such as inflammation and leukocyte trafficking, cancer-induced bone pain, and postsurgical pain, and also is a key factor in the cross-talking between tumor cells and their microenvironment. Aberrant overexpression of CXCR4 is critical for tumor survival, proliferation, angiogenesis, homing and metastasis. In this review, we summarized the role of CXCL12/CXCR4 in cancer, CXCR4 inhibitors under clinical study, and natural product CXCR4 antagonists. In conclusion, the CXCL12/CXCR4 signaling is important for tumor development and targeting the pathway might represent an effective approach to developing novel therapy in cancer treatment.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Biological Products / Chemistry / Receptors, CXCR4 / Drug Therapy / Chemokine CXCL12 / Molecular Targeted Therapy / Genetics / Metabolism / Neoplasms Limits: Animals / Humans Language: English Journal: Chinese Journal of Natural Medicines (English Ed.) Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Biological Products / Chemistry / Receptors, CXCR4 / Drug Therapy / Chemokine CXCL12 / Molecular Targeted Therapy / Genetics / Metabolism / Neoplasms Limits: Animals / Humans Language: English Journal: Chinese Journal of Natural Medicines (English Ed.) Year: 2018 Type: Article